Comparison of CSF biomarkers in multiple sclerosis patients treated with natalizumab and rituximab
Authors:
Open Access
- 1 May 2025
- journal article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 99, 106479
Abstract
No abstract availableKeywords
Funding Information
- Region Skåne
This publication has 36 references indexed in Scilit:
- COMBAT‐MS: A Population‐Based Observational Cohort Study Addressing the Benefit–Risk Balance of Multiple Sclerosis Therapies Compared with RituximabAnnals of Neurology, 2024
- Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple SclerosisJAMA Neurology, 2024
- Neurofilament Light Chain Elevation and Disability Progression in Multiple SclerosisJAMA Neurology, 2023
- Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple SclerosisJAMA Neurology, 2023
- Differences between blood and cerebrospinal fluid glial fibrillary Acidic protein levels: The effect of sample stabilityAlzheimer's & Dementia, 2022
- Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosisJournal of Neurology, 2019
- B‐cell Therapy for Multiple Sclerosis: Entering an eraAnnals of Neurology, 2017
- Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosisJournal of Neurology, 2011
- Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumabAnnals of Neurology, 2010
- Changes in B- and T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple SclerosisArchives of Neurology, 2010